Clinical Predictors of Early Cutaneous Melanoma Recurrence | Docwire News
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Related Articles
Subscribe | Docwire News
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care…
Pegcetacoplan Promotes Better Blood Counts and Fewer Transfusions for Patients With PNH | Docwire News
An interim analysis of the COMPLETE study found that pegcetacoplan improved indicators of blood health in patients with paroxysmal nocturnal hemoglobinuria.
Pegcetacoplan Shows Positive Results for Adolescents With C3G and IC-MPGN | Docwire News
Pegcetacoplan was found to reduce proteinuria and stabilize eGFR in adolescent patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis.
Dose Escalation Study Data Support Novel Calreticulin-Mutation-Targeting Antibody for High-Risk ET | Docwire News
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
Nefecon Demonstrates Kidney Benefits Independent of Baseline eGFR | Docwire News
Treatment effects of nefecon were consistent independent of baseline estimated glomerular filtration rate (eGFR) among patients with IgA nephropathy (IgAN).
Encouraging Phase 3 Data Released: Marstacimab for Hemophilia A or B With Inhibitors | Docwire News
In a cohort of adults and adolescents marstacimab produced bleed control superior to that from on-demand bypassing agent.
Pegcetacoplan Benefits Patients With C3G/IC-MPGN and Nephrotic Proteinuria | Docwire News
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3 glomerulopathy and primary immune complex membranoproliferative and nephrotic range proteinuria.
Real-World Data May Support Timely Caplacizumab for Safer, Faster Recovery in iTTP | Docwire News
The results are reported from an international cohort and support adding the agent to plasma exchange and immunosuppression.
Patterns in Checkpoint Inhibitor Kidney Inflammation Identified | Docwire News
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis (ICI-AIN) with differing clinicobiological presentations and outcomes.
Phase 1 Trial of Fetal Hemoglobin-Increasing Agent for SCD Begins | Docwire News
The agent notably in preclinical studies has accomplished increased HbF without any evident cytotoxicity.